Natural killer (NK) cells were viewed traditionally as cytotoxic effector cells whose rapid killing of infected and transformed cells without preactivation provides a first line of defense prior to the initiation of an adaptive immune response against infection and tumor development. However, it has become clear that NK cells interact with various components of the immune system, and therefore have the potential to function as regulatory cells. While NK cells can assist in dendritic cell (DC) maturation and T-cell polarization, increasing evidence indicates that NK cells can also prevent and limit adaptive (auto) immune responses via killing of autologous myeloid and lymphoid cells. Investigating immunoregulatory NK-cell functions might generate exciting insights into the reciprocal regulation between NK-cell-mediated innate immunity and adaptive immune responses, improve our capacity to monitor these cells as surrogate markers for disease activity and treatment responses in autoimmune diseases, and, perhaps, provide new prospects for NK cell-directed therapies.
PHENOTYPES AND FUNCTIONS OF NK CELLS IN HUMANS
Although NK cells were described originally as a homogenous population of innate lymphocytes, there is increasing evidence that NK cells include distinct subsets with disparate functions, locations, and developmental origins. Human NK cells in peripheral blood can be divided into at least two functional subsets based on the expression of CD56 and CD16 (Figure 1 (14) (15) (16) (17) . DCs can activate resting NK cells directly, by cell-to-cell contact; and indirectly, via the secretion of cytokines such as type I IFNs, IL-12, IL-15, and IL-18. Among the soluble factors, IL-12 has been observed to induce IFN-γ secretion and proliferation repeatedly, and was thought to be the most pivotal signal-enhancing factor for NK-cell effector functions in humans and in mice (15, (18) (19) (20) (21) . IL-15 appears to determine NK cell differentiation and survival, thereby possibly promoting NK-cell expansion (15, 22, 23) . In addition, type I IFNs were suggested primarily to augment NK-cell cytotoxicity (24) , but IL-12 can also contribute to enhancing this NK-cell function (21 (26, 27) , which promote priming and expansion of CD8 + T cells (28) . On the other hand, activated NK cells can kill autologous immature myeloid DCs via NKp30-, NKp46-, and DNAM-1-mediated recognition (29) (30) (31) . Resistance to NK lysis was achieved via upregulation of MHC class I molecules upon DC maturation, in particular, upregulation of HLA-E (32), suggesting that NK cells expressing the inhibitory recep- 
NK-CELL FUNCTION IN EXPERIMENTAL AUTOIMMUNE DISEASES
Because of the lack of mouse strains that are selectively deficient in NK cells, the study of NK-cell function in vivo has been challenging in the past (46) . Animal models of autoimmune diseases provide evidence for both disease-accelerating and disease-protective effects of NK cells (Figure 2 ). The contradictory results achieved by NK-cell depletion are best illustrated in EAE, the animal model of multiple sclerosis (MS). It has been suggested that NK cells could be pathogenic by shaping Th1-polarized adaptive immune responses and by activating CNSinfiltrating DCs (47) . Indeed, several mouse strains which have defective NKcell functions, such as IL-18 deficient mice, or that are devoid of NK cells, such as T-bet deficient mice, are resistant to EAE induction (48, 49) . Surprisingly, most studies in the EAE model reported that NK cells protect from autoimmunemediated tissue damage, presumably by editing initiator and effector cell populations (45, (50) (51) (52) . Antibody-mediated depletion of NK cells exacerbated EAE pathology in Lewis rats, SJL mice, and C57BL/6 mice (50,51,53), whereas adoptive transfer of in vitro-generated NK cells from the bone marrow decreased the severity of EAE in DA rats (54) . Furthermore, it was observed that NK-cell depletion resulted in increased proliferation and IFN-γ production of T cells specific for the antigen that was used to induce EAE (50) . Interestingly, opposite findings were observed in a different study using the same mouse strain immunized with the same myelin antigen (47) . Contradictory findings on the effects of NK-cell depletion also were reported in animal models of type 1 diabetes (T1D). Whereas antibody-mediated NK-cell depletion was protective in one study (55) , another report suggested that NK cells protect from T1D through secretion of perforin, IFN-γ, or immunoregulatory cytokines (56, 57) . Such apparently controversial findings might be explained, at least in part, by differences in the model system used to determine NKcell function. For EAE induction, timing of myelin immunization and NK-cell activation/depletion could be critical for the outcome; NK cells could modulate and suppress T-cell polarization and effector function during the initiation of autoimmune responses against autoantigens, but might contribute to immunopathology by directly causing tissue damage during progression of the established disease. In addition, using different tools and protocols to achieve NK-cell depletion could explain different outcomes. Unfortunately, no antibody targets NK cells specifically. The most frequently used antibodies for NK-cell depletion target NK1.1 and asialo-GM1, which also are expressed on natural killer T cells (NKT cells) and a subset of cytotoxic T cells, respectively. Moreover, antibody-mediated NK-cell depletion could be preceded by NK-cell activation and IFN-γ production, or might preferentially target distinct subsets of NK cells that mediate divergent effects on EAE initiation and progression. Studies in mice which allow selective in vivo ablation of NK cells (46) might be helpful in better characterizing the functional impact of NK cells on the initiation and progression of experimental autoimmune diseases in the future.
NK-CELL (DYS)FUNCTION IN HUMAN AUTOIMMUNE DISEASES
Several studies reported that individuals with autoimmune diseases such as MS and systemic lupus erythematosus (SLE), have fewer blood NK cells compared with healthy subjects. Moreover, NK cells isolated from patients with MS were found not only to be decreased in frequency, but also to be impaired in effector function (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) . Notably, patients with hemophagocytic lymphohistiocytosis (HLH), a rare condition characterized by impaired or absent function of the perforin/ granzyme system in NK cells and cytotoxic T-cells, demonstrated decreased NKcell activity. This resulted in increased T-cell and sustained-macrophage activation, and in the production of large quantities of the lymphokines IFN-γ, TNF-α, and GM-CSF, as well as of IL-1 and IL-6 (69). The macro phage activation syndrome (MAS), now considered a special form of HLH, occurs in children and adults with autoimmune diseases, especially systemic juvenile rheumatoid arthritis (sJRA) (70) . Interestingly, patients with sJRA show decreased NK-cell frequencies and impaired NK-cell functions compared with children with other forms of juvenile rheumatoid arthritis such as pauciarticular and polyarticular JRA, even in the absence of MAS (71, 72) , which can, however, be triggered by environmental insults such as viral infections (73) . Thus, patients with HLH and sJRA represent an example for an association of NK-cell dysfunction and excessive immune activation, which could contribute, potentially, to the initiation and maintenance of autoimmune responses.
On the other hand, there are many studies which found no differences in NK-cell frequencies and functions in patients with common autoimmune diseases compared with healthy controls (74) (75) (76) (77) . These contradictory findings are difficult to interpret since all of the aforementioned studies differed widely in their criteria used to classify NK cells. Some of the older reports did not distinguish between NK cells and NKT cells and none of the above studies differentiated between CD56 bright CD16 -and CD56 dim CD16 + NK cells. Moreover, the assays and protocols used to study NK cell frequencies and functions, as well as the patient populations studied, varied significantly (78) . With these caveats in mind, genetic predisposition for autoimmune diseases has been linked to NK cells, and successful therapies of autoimmune diseases correlated with changes in the NK-cell compartment. The genetic analysis of NK cells has focused mainly on KIR allele typing. KIRs are expressed on NK cells and subsets of T cells. The KIR genes are extremely polymorphic, probably more than the HLA loci, and the KIR gene complex is polygenic with varying numbers of inhibitory and activating receptors (79) . HLA class I molecules serve as ligands for the KIR. Interactions of the independently segregating KIR and HLA loci are important for recognition of targets by NK cells. Several studies correlated incidence and progression of infectious and autoimmune diseases with the expression of particu- lar KIRs, as well as with HLA-KIR combinations. For example, in patients with psoriasis and psoriatic arthritis, conditions that have long been associated with HLA-C, specifically with the C2 allotype gene HLA-Cw*06, it has been reported that activating KIR genes (usually KIR2DS1 and/or KIR2DS2) are at a higher frequency in patients than in healthy control individuals (80, 81) . These studies suggest that the overall balance of activating and inhibitory composite KIR-HLA genotypes contributes to the susceptibility toward autoimmune diseases. However, it remains to be defined whether these genotypes also translate into functional differences (82) .
Stronger evidence for a regulatory role of NK cells in MS stems from immunomonitoring of a phase II therapy trial in MS. The rationale for the use of a humanized IgG1 monoclonal antibody targeting the interleukin-2 receptor α chain (daclizumab) in patients with autoimmune diseases such as MS was to block the proliferation of antigen-activated autoreactive T cells. Indeed, results of four open-label studies of intravenous daclizumab in patients with active forms of either RRMS or secondary progressive MS (SPMS) have suggested beneficial effects of daclizumab for both add-on and monotherapy protocols as measured by magnetic resonance imaging (MRI) and clinical outcomes (83) . NK cells include distinct subsets with disparate repertoires, location, function, and developmental origin. In analogy to regulatory T-cell subsets, NK-cell subpopulations that have yet to be characterized might be particularly important in regulating autoimmune inflammation. We suggest that investigating immuno regulatory NK-cell functions in healthy individuals and patients with autoimmune diseases will generate exciting insights into the reciprocal regulation between NK-cell-mediated innate immunity and adaptive immune responses, improve our capacity to monitor these cells as surrogate markers for disease activity and treatment response, and, perhaps, provide new prospects for NK-cell-directed therapies.
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